The clinical efficacy of salvia officinalis
An evaluation of the clinical efficacy of Salvia officinalis, Salvia lavandulaefolia and Melissa officinalis for the prophylaxis, management and amelioration of cognitive dysfunction: with particular reference to Alzheimer’s disease and non-Alzheimer-type senile dementias.
Dementia is a collection of symptoms caused by a chronic, global deterioration of cognitive function. It can occur at any age but is most prevalent in the elderly and increases with age (Beers et al. 2006: 1811). Around 5% of people over 65, 25% over 80 and 45% over 85 have some form of dementia (Knapp et al. 2007: 10; Collins 1997: 185). The population is aging and whereas today there is an estimated 700,000 people in the UK suffering from dementia, this number is set to increase to more than a million by 2025. The huge impact dementia has on society, devastating families and costing around £17-18 million annually cannot be overstated (Knapp et al. 11). Early identification and safe, effective, intervention is therefore important.
Dementia may be classified as Alzheimer’s or non-Alzheimer-types (Beers et al. 2006: 1811). The most common dementia is Alzheimer’s disease (AD) (Grossman et al. 2006: 985), affecting around 20 million people worldwide (Akhondzadeh et al. 2003: 53) and accounting for around 62% of dementias (Knapp et al. 2007: 11). Non-Alzheimer-type dementias typically affecting those over 60 include vascular dementia (27%), Lewy body dementia and fronto-temporal dementia (Knapp et al. 29).
Cognitive disorders are treated allopathically with drugs that have yet to show real benefits and have a number of side-effects and contraindications. The need for safer, more effective treatments has led to increasing interest in the use of herbs for their management (Akhondzadeh and Abbasi 2006: 117). A variety of herbs, for example Salvia officinalis, Rosmarinus officinalis, Mellissa officinalis, Ginkgo biloba (Heinrich et al 2004: 234), Withania somnifera (Howes et al. 2003: 12), Centella asiatica (Chevallier 1996: 78) and Panax ginseng (Mantle et al. 2000: 207) have long-standing traditional use as memory-enhancing herbs. Consequently a number of clinical studies have been conducted to assess the efficacy of some of these herbs, most notably Ginkgo biloba, Salvia spp. and Mellissa officinalis, in the treatment of cognitive disorders. Of these, only clinical trials of Gingko biloba have been extensively reviewed (Birks and Grimley Evans 2002; Ernst et al. 1999; Oken et al. 1998). This present review aims to fill this gap by providing up-to-date information on whether clinical studies of Salvia spp. and Mellissa officinalis support their traditional use as cognition enhancers. To inform herbal practice it will evaluate clinical studies to assess whether the results have determined safe, effective herbal strategies and prescription for prophylaxis, management and amelioration of cognitive decline.
2. The literature review
2.1. Background: clinical presentation and pathology
Although much scientific progress has been made since 1907 when Alois Alzheimer first described a case of dementia with “peculiar patches” disseminated throughout the cerebral cortex (Collins 1997: 185), there is still much to learn about the aetiology and pathogenesis of Alzheimer’s disease and other dementias (Knapp et al. 2007: 11).
The onset of dementia is insidious, often beginning as mild cognitive impairment (MCI) and progressing to severe dementia over time (Loveman et al. 2006: 4). In the early stages, episodes of mild forgetfulness or misplacing possessions are often attributed to normal aging. Patients commonly suffer from anomic aplasia and agnosia but retain language comprehension (Collins 1997: 186). Dementia becomes more apparent when sufferers are unable to learn new information, to register the content of a conversation, or to recall recent events or the names of family members. Unlike those with benign forgetfulness, dementia patients are unaware of their amnesia. Frequently, there are mood changes, depression and other psychologic disturbances. Language comprehension fails (aphasia) and eventually patients may simply repeat what they hear or be unable to speak at all. Visuospacial deficits usually occur at a late stage (Collins 1997: 186). Those affected have difficulty in copy drawing simple objects.
Differential diagnosis between MCI subtypes of various and complex aetiologies is challenging (Kidd 1999: 145). As some MCI subtypes are reversible (Levey et al. 2006: 992) prophylaxis for dementia could potentially encompass a range of varied or unknown aetiologies and risk factors. Knowledge of these and an awareness of differing clinical presentations are therefore important (Levey et al: 991). Additionally, an understanding of current orthodox treatment strategies and key neurochemical impairments in dementia can inform herbal practice of the most likely therapeutic actions of herbs.
2.1.1. Alzheimer’s disease
As clinical studies have indicated that mild to moderate Alzheimer’s disease (AD) responds better to allopathic drugs than severe AD (Levey et al: 2006: 993), to prevent transition of MCI to AD early diagnosis is important. Evidence suggests that MCI associated with memory loss most commonly leads to AD (Levey et al. 991) and results of a clinicopathologic study of 80 subjects with MCI through to autopsy suggest that depression is one of the first features of AD (Galvin et al. 2005: 763). Formation of diffuse neuritic senile plaques in the brain is characteristic of AD but as these can only be determined from biopsy (Collins 1997: 186) probable diagnosis is made by clinical neuropsychological testing (Grossman et al. 2006: 986) such as the Mini Mental state Examination (MMSE) (Alzheimer’s Society 2002: 436), while magnetic resonance imaging can corroborate diagnosis by identifying areas of temporal neuronal loss (Vandenberghe and Tournay 2004: 347).
Progression of AD is unremitting for around 5-10 years until death ensues. In the final stages sufferers may develop apraxia, with difficulty in performing familiar tasks. A common cause of death is pneumonia when patients’ eventual difficulty with eating results in aspiration pneumonia (Collins 1997: 186). The loss of faculties has been ascribed to both structural and neurochemical abnormalities (Perry et al. 1996: 1063).
Senile plaques in the brains of AD patients contain amyloid and tau protein (microtubule associated protein) (Collins 1997: 188). Since isolation of b-amyloid peptide from cerebral vessels in AD patients (Wong et al. 1984: 8729), the accepted hypothesis for the pathogenesis of AD has been the ‘amyloid hypothesis’, which proposes that AD is due to excessive formation of extracellular b-amyloid (Ab?) from amyloid precursor protein (APP), a membrane protein in neurons (Grossman et al. 2006: 986). It is thought that Ab molecules initiate a toxic cascade long before plaque forms by causing an inflammatory reaction, disrupting synaptic function and causing neurons to degenerate (Grossman et al. 986) with a loss of cholinergic fibres in the basal forebrain. In vitro results suggest that Ab enters mitochondria and induces free radical damage (Reddy 2006: 9). Intracellular neurofibrillary tangles are believed to be formed by abnormal phosphorylation of tau proteins (Tanzi and Bertram 2005: 545), particularly in the hippocampus and neocortex, areas of the brain involved in memory (Mantle et al. 2000: 202).
To date, thirteen genes have been implicated in AD (Bertram et al. 2007: 17). Of sporadic late onset Alzheimer’s up to 40% of cases may be due to a faulty gene on chromosome 21, ApoE4, an isoform of the ApoE gene that encodes for apolipoprotein, an astrocytic protein that may play a role in the reparative process in the brain. ApoE4’s pathogenetic mechanism may be to enhance amyloid deposits within tissue by accelerating cleavage of b-peptide (Collins 1997: 189). Possession of a gene implicated in AD does not necessarily result in its development, the likelihood of which is further complicated by the potential role of environmental factors such as viruses and toxins in combination with genetic factors (Bird 2005: 864).
2.1.2. Vascular dementia
Vascular dementia (VaD) is any type of dementia caused by cerebral blood vessel disease (Micieli 2006: S37). Onset of VaD is usually abrupt. Imaging may reveal areas of multiple infarcts (Collins 1997: 191) but their presence does not necessarily imply dementia (Grossman 2006: 987). According to Looi and Sachdev (1999) it is not possible to differentiate between AD and VaD with neuropsychological testing. Speech and language difficulties associated with vascular dementia may be mild or there may be a more pronounced aphasia as in multi-infarct VaD (Collins 1997: 191).
2.1.3. Frontal lobe dementia
Frontal lobe dementia or Pick’s disease is uncommon and is characterised by neuronal loss and gliosis. Rarely, there are fibrillary inclusion bodies in the neurons. Presentation of frontal lobe dementia differs from AD in that the first symptoms are a change in personality rather than memory loss (Collins 1997: 193).
2.1.4. Lewy body dementias
Dementia with Lewy bodies may differ to AD in its presentation in that patients suffer from marked visual hallucinations. Additionally, cognition tends to fluctuate between normality and confusion. Parkinsonian features such as shuffling gait, tremor, bradykinesia and rigidity are prevalent. Sleep behaviour disorder, such as acting out attacking themes, may appear years before other signs of the disease (Grossman et al. 2006: 989).
2.2. Risk factors
Factors believed to pose a risk for developing dementia include cardiovascular disease, being female, a family history of dementia, Down’s syndrome, older age, head trauma, diabetes and lower educational standards (Collins 1997: 186, 188; Lebson et al. 1997: 301).
2.2.1. Cardiovascular disease: Patients may have more than one type of dementia concurrently (Beers et al. 2006: 1811). This is compounded by results of a number of epidemiological studies suggesting that cardiovascular disease increases the risk of developing AD (Stampfer 2006: 12). Using transcranial Doppler ultrasonography Sun et al. (2007: 152) demonstrated diminished cerebral blood flow velocities in MCI patients who also carried the ApoeE4 allele.
Risk factors for VaD are believed to include artherogenic factors such as hypertension, hyperlipidaemia, diabetes, and cigarette smoking (Micieli 2006: S38). Conversely, there are indications from clinical trials that nicotine has a protective effect for AD (Breteler et al. 1992: 71). Results of a randomised, double-blind, multicentred trial in which subjects with hypertension were treated with antihypertensives or placebo suggest that hypertension is a risk factor for developing both AD and VaD. Antihypertensives reduced risk by 55%. The results were significant as subjects had similar characteristics, the sample size was large (3228) and equally divided into placebo and treatment groups. Median follow-up was 3.9 years (Forette et al. 2002: 2047).
2.2.2. Head trauma: A meta-analysis by Fleminger et al. (2003: 858) replicated earlier findings by Mortimer et al. (1991) that head injuries pose a risk for AD but only in males, thought to be due to an early protective effect of oestrogens in females (Fleminger et al. 860). Bias may have been introduced into both studies as informants recalled the injuries.
2.2.3. Diabetes mellitus: Given that diabetes mellitus (DM) is a known risk factor for vascular disease it is not surprising that most studies on the development of vascular dementia in DM patients have shown a positive association (Biessels 2004: 10). Studies on DM as a risk factor for AD, however, have yielded conflicting results, possibly due to study limitations such as small sample sizes and selection bias (Leibson et al. 1997: 301). Large longitudinal studies may be more reliable. A population-based historical cohort study of 1,455 cases followed over 9,981 person years found a statistically significant positive association (Leibson et al. 304). According to results from the Framlingham Study, diabetes may not be an independent risk factor for developing AD but risk is strongly associated with possession of the ApoE4 genotype (Akomlafe et al. 2006: 1551).
2.2.4. Hormones: Women are twice more likely than men to suffer from AD. Although this may be partly due to women having a longer life expectancy (Beers et al. 2006: 1814) there is evidence to suggest that a decline in endogenous oestrogen in later life plays a role in its pathogenesis. Oestrogen is believed to stimulate cholinergic activity, reduce oxidative stress related cell damage, reduce vascular risks, reduce Ab formation and promote synaptic activity (Zandi et al. 2002: 2123; Hoskin et al. 2004: 141). Evidence from studies to determine whether oestrogen-containing hormone replacement therapy (HRT) in women has a protective effect on the brain, however, is conflicting (Colucci et al. 2006: 1376) but this may be due to differences in methodology and confounding factors (Resnick and Henderson 2002: 2171). For example, in one large prospective study that found a positive correlation between HRT use and a significant reduction in AD development, patients with dementia were asked questions regarding previous use of HRT (Zandi et al. 2124) yet accurate recall in a dementia sufferer cannot be guaranteed. Results of a retrospective case-control study suggesting the likelihood of women developing AD increases with number of pregnancies (Colucci et al. 2006: 1375) could be of little value. Cases with previous head injuries, low educational standards, both considered risk factors for AD (Collins 1997: 186; Fleminger et al. 2003: 858), and those who had used HRT, were not excluded from the study.
There is evidence to suggest testosterone may delay AD onset in men. Men over 32 years of age who were free from AD at baseline (n = 574) were followed for a mean of nineteen years (Moffat et al. 2004: 188). Long-term free testosterone levels were significantly lower in men who developed AD.
Due to conflicting results and confounding factors in the research the clinical evidence for risk factors for dementia is inconclusive. However, although more research is needed the results can assist in informing herbal practice.
2.3. Orthodox treatment strategies
As cholinergic neurotransmitters are believed to have a role in memory function (Grossman et al. 2006: 985) symptomatic treatment for subtypes of dementia is similar and focuses on acetylcholinesterase (AChE) inhibition with drugs such as donepezil, rivastigmine and galantamine (Loveman et al. 2006: 8). According to Delagarza (2003: 1366) loss of cholinergic neurons causes a decrease in acetylcholine and subsequent drop in AChE with a compensatory rise in butylcholinesterase (BChE). Nicotinic receptors also decrease. Rivastigmine also inhibits BChE; galantamine also acts on nicotinic receptors. Depression in dementia is treated with non-anticholinergic antidepressants as anticholinergic drugs exacerbate symptoms (Beers et al. 2006: 1814). Another drug, memantine, a N-methyl-D-aspartic acid (NMDA) receptor antagonist (Grossman et al. 987), licensed to treat moderate to severe AD, acts by modulating the action of the neurotransmitter glutamate, which is believed to be associated with cholinergic damage and neurodegeneration when secreted in excess (Loveman et al. 2006: 8).
Dizziness, diarrhoea, headaches, nausea and vomiting were found by a meta-analysis of dementia drugs to be common adverse events with anti-cholinesterases and memantine (Loveman et al. 2006: 49). Furthermore, their long-term benefits are inconclusive (Loveman et al. 145). Similarly, their use for vascular or Lewy body dementia is controversial as a review of clinical trials data deems there is insufficient evidence for their efficacy. Trials were of generally poor quality and with inconsistent findings (Maggini et al. 2006: 457).
Other potential drugs for AD include 70 new compounds formulated to interfere with the toxic amyloid cascade or to target inflammation, oxidation or apoptosis (Grossman et al 2006: 987). As g-aminobutyric acid (GABA) agonists can impair memory GABA antagonists are also being developed (Association of the British Pharmaceutical Industry).
2.4. Potential herbal treatment strategies
In view of the hypothesised pathological sequelae, risk factors and current orthodox treatment of dementias, efficacious herbs for these conditions could potentially have one or more of AChE-inhibiting or cholinergic, antidepressant, hypotensive, hypoglycaemic, antioxidant, anti-inflammatory, GABA modulator, nicotinic agonist, testosterogenic and oestrogenic actions.
According to Kennedy and Scholey (2006: 4614) orthodox AChE inhibitors are not well tolerated by patients as they are toxic alkaloids and European plants traditionally used for cognitive enhancement may therefore provide non-alkaloid safer alternatives. To this end Salvia officinalis, Salvia lavandulaefolia and Melissa officinalis, members of the Labiatae family (Lamiaceae), have been extensively investigated in vitro.
2.4.1. Salvia spp.
Salvia is the largest genus in the Labiatae family with over 700 species. The most common European species are Salvia officinalis L (garden or common sage) (Figure 1) and Salvia lavandulaefolia Vahl (Spanish sage), both of which originate on the shores of the Mediterranean (Kennedy and Scholey 2006: 4614). S. officinalis is an aromatic, evergreen shrub up to 75 cm in height with greyish-green oblong to lanceolate opposite leaves covered in a fine down. It has bluish-violet, two-lipped flowers arranged in whorls (Wildwood 1998: 202). S. lavandulaefolia has narrower leaves and a lower spreading habit (Sergei Savelev’s Database).
Sage was used in medieval Europe as a tisane for prolonging life and is a traditional spring tonic for strengthening weak constitutions (Lipp 1996: 63). According to Culpepper (1826: 147) ‘Sage is of excellent use to help the memory, warming and quickening the senses…’ and an old country remedy, which indicates its efficacy for inflammation: ‘A sunburnt face is eased by washing with sage tea’ (Page 1978: 41). Other traditional uses are for headaches and migraine (Page: 34).
The major active constituents of the leaves of both species are believed to be the volatile oils (1.0-2.8%), containing monoterpenes such as a-pinene, b-pinene, 1-8-cineole, camphor, geraniol and thujone (Kennedy and Scholey 2006: 4615). S. officinalis contains around 50% a- and b- thujone whereas only traces have been found in S. lavandulaefolia. As thujone, a terpenoid ketone, is potentially neurotoxic, S. lavandulaefolia may provide a safer alternative than S. officinalis to orthodox dementia drugs (Perry et al. 1999: 530). However, S. officinalis is toxic only at doses of over 15 g (Grainger-Bissett and Wichtl 2001: 441) but the oil should not be ingested. Both species contain polyphenolic compounds including rosmarinic acid, methyl carnosate, luteolin, luteolin-7-0-glucoside and caffeic acid (Kennedy and Scholey 4615), triterpenes eg oleanic acid and the flavonoids 5-Methoxysalvagenin (Barnes et al. 2002: 408) and hispidulin (Johnston and Beart 2004: 809).
2.4.2. Melissa officinalis
M. officinalis L (balm, lemon balm) (Figure 2) originates from the eastern Mediterranean region and western Asia and is now widely cultivated in the west (Grainger Bissett and Wichtl 2001: 329). It is a bushy perennial, about 60 cm high with bright green, lemon-scented leaves in opposite pairs. Small labiate flowers grow in whorls and change colour from pale yellow to white or pale blue. Fresh leaves should be collected when young (Wildwood 1998: 175). It has been in medicinal use as a nervous system restorative for over 2000 years (Kennedy and Scholey 2006: 4617). The London Dispensary (1696 cited in Grieve 1931) states: ‘An essence of Balm, given in Canary wine every morning will renew youth, strengthen the brain…’ John Evelyn wrote: ‘Balm is sovereign for the brain, strengthening the memory and powerfully chasing away melancholy’ (cited in Grieve 1931). There are no known contraindications or adverse effects (Barnes et al. 2002: 339).
M. officinalis contains 0.2-0.3% essential oil (EO) consisting of over 70 components including around 60% monoterpenoid aldehydes and over 35% sesquiterpenes. The principle monoterpenes include citronellol, neral, geranial, methyl citronellate, ocimene; major sesquiterpenes include b-caryophylene and germacrene D. The herb also contains flavonoids, caffeic and chlorogenic glycosides, polyphenolic acids such as rosmarinic acid, and triterpenes (Granger Bissett and Wichtl 2001: 330).
2.5. Possible mode of action of phytochemical constituents in dementia
2.5.1. Antioxidant properties
Numerous studies have been conducted on Salvia officinalis in a search for natural antioxidants to use in the food industry. Consequently, results of chemical tests on purified extracts of the herb have suggested that phenolic compounds rosmarinic acid, carnosic acid, carnosol, carnosoic acid, rosmadiol, rosmanol, epirosmanol, isorosmanol, galdosol methyl carnosate, 9-erythrosmanol and luteolin-7-0-glucopyranoside have significant antioxidant activity (Bertelsen et al 1995: 1272; Cuvelier et al. 1994: 665; Pizzale et al. 2002: 1651; Miura et al. 2002: 1848; Wang et al. 1998: 4869).
S. lavandulaefolia dried leaf extracts in ethanol, chloroform and water, and various EO monoterpenes were assayed for antioxidant properties in phospholipid microsomes. The extracts and monoterpenes a-pinene, b-pinene, 1-8-cineole, camphor and geraniol and thujone all showed significant antioxidant activity (Perry et al. 2001: 1351). The extracts showed greater antioxidant activity than any individual monoterpenes, which suggested a synergistic effect (Perry et al. 1352).
Ferreira et al. (2006: 35) measured the antioxidant properties of EOs, decoctions and ethanolic extracts of M. officinalis and S. officinalis relative to b-carotene. The EO and decoctions of both herbs showed significant antioxidant activity. Lima et al (2007) found methanolic and aqueous extracts of S. officinalis prevented lipid peroxidation in hepatoma cells. As there were more phenolics in the methanol extract it was thought there were other antioxidant compounds in the aqueous extract.
Ethanolic EO extract from dried M. officinalis investigated for its ability to inhibit lipid peroxidation in vitro showed a dose-dependent (10-20 mg) 80-90% protection of linoleic acid from peroxyl radical attack. As no rosmarinic acid was detected in the EO the antioxidant action was attributed to squalene (Marongiu et al. 2004: 790). Considering there are potentially 70 constituents in the EO it is unlikely that this would have been the only active phytochemical but composition of the oil varies according to harvesting, origin and climate (Grainger-Bissett and Wichtl 2001: 329). Interestingly, M. officinalis prepared as a tea demonstrated significant antioxidant capacity, which corresponded to high phenolic content, when assayed with the ABTS (2,2/-azinobis 3-ethylbenzothiazoline-6-sulfonic acid) radical decolourisation assay (Ivanova et al. 2005: 147).
2.5.2. Anti-inflammatory activity
Chloroform, aqueous and ethanol extracts and monoterpenes of S. lavandulaefolia, were tested for their ability to inhibit formation of pro-inflammatory eicosanoids thromboxane B2 (TXB2) and leukotriene B4 (LTB4) in leucocytes (Perry et al. 2001: 1348). The chloroform and ethanol extracts showed significant inhibition of LTB4. Alpha-pinene and geraniol showed weak selectivity for LTB4 and TXB2 respectively (Perry et al. 1351). The results support the traditional use of S. lavandulaefolia as an anti-inflammatory herb but indicate that it is the sum of the whole plant phytochemicals acting in synergy that are likely to contribute to this action.
A standardised ethanolic extract containing 9.9% rosmarinic acid (RA) from the leaves of S. officinalis reduced Ab-induced neuronal cell death, Ab-induced lipid peroxidation, reactive oxygen species formation, DNA fragmentation and tau protein hyperphosphorylation in vitro (Iuvone et al. 2006: 1143). Kimura et al (1987) found rosmarinic acid (RA) had the ability to inhibit pro-inflammatory cytokines in human polymorphonuclear leucocytes (PMNs) in vitro. As both species contain RA these results suggest antioxidant, anti-inflammatory and neuroprotective properties of M. officinalis and the Salvia spp. against Ab-induced neurotoxicity.
2.5.3. Oestrogenic activity
A range of concentrations of EO, ethanolic, chloroform and aqueous extracts and isolated monoterpenes of S. lavandulaefolia were assayed in yeast culture for oestrogen-binding properties. The EO showed weak oestrogenic activity at low concentrations. The aqueous and ethanolic fractions and geraniol showed significant oestrogenic activity (Perry et al. 2001: 1352). The results of this experiment support S. lavandulaefolia’s use as an oestrogenic herb.
The effects of S. officinalis in combination with Medicago sativa were assessed on menopausal symptoms related to oestrogen deprivation. Hot flushes and night sweats were completely eliminated in 20 out of 30 women (De Leo et al. 1998: 207). These effects were attributed to dopaminergic actions but it is not clear for which herb. S. officinalis does, however, contain geraniol found to be oestrogenic in vitro (Perry et al. 2001: 1352).
2.5.4. Acetylcholinesterase inhibitory activity
M. officinalis EO demonstrated strong AChE inhibition in homogenised human brain tissue but ethanolic extract of the dried leaf had no effect. Ethanolic fresh leaf extract showed a weak effect (Perry et al. 1996: 1064). Conversely, when EOs and ethanolic extracts of M. officinalis were assayed in solution with AChE negligible results were obtained for its inhibition by EO and significant results for its ethanolic extract (Ferreira et al. 2006: 34). Dried, reconstituted ethanolic, ethyl acetate or aqueous extracts of M. officinalis, yielding 10mg/ml, demonstrated weak AChE inhibitory activity when assayed in a chemical system using thin layer chromatography (Salah and Jäger 2005: 146). The herbs were purchased from local suppliers in the Lebanon so their quality is unknown.
S. officinalis EO and ethanolic extract assayed in solution with AChE showed moderate AChE inhibitory activity (Ferreira et al. 2006: 34). Moderate (dose-dependent) AChE and weak BChE inhibition was demonstrated by ethanolic extracts of fresh and dried S. officinalis and S. lavandulaefolia in human brain homogenates. The EOs had significant effects but not the individual constituents (camphor, thujone, cineole, caffeic acid and borneol) (Perry et al. 1996: 1066). The findings suggest a major synergistic effect of the constituents (Perry et al. 2000: 895), which was later confirmed by Savelev et al. (2003: 667). The results for camphor conflict with another experiment in which S. lavandulaefolia EO and isolated monoterpenes a-pinene, 1-8-cineole and camphor demonstrated AChE inhibitory activity in human erythrocytes.
Ethanolic extracts of dried S. officinalis, S. lavandulaefolia and M. officinalis were assayed for acetylcholine (ACh) receptor activity in human brain homogenate. All plants demonstrated ACh receptor activity and M. officinalis had the highest nicotinic displacement value (Wake et al. 2000: 108).
2.5.5. GABA modulation
Methanol extract from S officinalis leaves revealed the flavonoids apigenin, hispidulin and cirsimaritin functioning as benzodiazepine receptor-active components (Kavvadias et al. 2003: 113), suggesting a potential calming effect for the herb, which may be relevant to AD.
2.6. Evaluation of in vitro studies
According to the results all three herbs may have AChE inhibitory, anti-inflammatory and antioxidant properties, and S. lavandulaefolia and S. officinalis may have and oestrogenic properties (Appendix I, Table 1, page 36) and a sedative effect for S. officinalis.
Although these results are interesting in vitro systems cannot be extrapolated to humans and clinical evidence is necessary to support findings. For example, they cannot determine effective human dosage or mode of administration. They largely do not account for potential synergistic effects of the herbs nor do they provide an indication of in vivo physiological, pathological and genetic, or environmental, influences. Furthermore, the extent to which phytochemicals in herbs are effective in dementia may depend upon their bioavailability in the brain (Anekonda and Reddy 2005: 371). It is worth noting, however, that as terpenoids tend to be lipophilic they are able to cross the blood brain barrier (Houghton and Howes 2005: 12).
Some results are conflicting but they may depend on methodological quality and design. The experiments cited above vary widely in their approach with regard to extraction methods and assay methods. Savelev (2003: 667) has demonstrated how two different methods used for exploring interactions between the same agents may give different results when applied to the same set of data. Consistency of results may also be affected by differences in harvesting times and quality of herbs. Results for M. officinalis are particularly inconsistent but, according to Perry et al. (1996: 1068) most commercial sources of the EO are adulterated. Additionally, variation in media composition is known to affect the outcome of in vitro tests (Maurer and Kuschinsky 2006: 73). Consequently, in vitro experiments can only provide an indication of the clinical efficacy of therapeutic interventions. However, despite the inherent difficulties of in vitro research with herbs, there is considerable consistency with their potential value in dementia prophylaxis and management (Appendix I, Table I, page 36).
Promising results in vitro of constituents of plants traditionally used to enhance memory, and subsequent interest in their potential actions in the brains of human patients, has generated clinical trials of M. officinalis and Salvia spp. for dementia. These will be reviewed.
A computerised literature search was conducted on the Allied and Complementary Medicine Database (AMED) including CINAHL Database, EMBASE, Pascal Biomed, Biological Abstracts, RCN Journals Database and IPA (International Pharmaceutical Abstracts); PubMed, the Cochrane Collaboration, Bandolier, the NHS Centre for Reviews, The National Research Register, ADEAR (Alzheimer’s Disease Education and Referral Centre database), PLoS (Public Library of Science), Herbalgram and Alt HealthWatch as well as hand-searching in books and journals. Literature searches dated back to 1985 and the final search was in April 2007.
Key words in medical subject headings (MeSH) for an initial search in various Boolean combinations were: memory, cognitive dysfunction, dementia, Alzheimer’s, herbal, botanicals, phytotherapy, complementary and alternative. Also, in a second search these MeSh terms were entered with key herbs: Salvia, sage, Melissa and lemon balm.
- Controlled clinical trials, observational studies and case reports.
- Herbs for which there are at least two clinical studies in relation to cognitive enhancement.
- Due to the limitations and ethical considerations of animal experiments the review is restricted to human trials.
- Trials with combined preparations are excluded.
- Due to time constraints and a restriction to papers in the English language a complete systematic review is not viable at this time.
- To eliminate the potential for introduction of bias the results of systematic reviews and meta-analyses are not included. For example, systematic reviews of the efficacy of Ginkgo biloba for dementia and cognitive dysfunction have already been conducted (Birks and Grimley Evans 2002; Ernst et al. 1999; Oken et al. 1998).
- Herbs traditionally used for cognitive enhancement but for which there is insufficient clinical research are excluded.
Evaluation of studies considered the following aspects:
- Sample size, duration of the study and statistical significance.
- How the therapeutic intervention was compared eg placebo or drug.
- Overall quality of the methodology and techniques used, including potential confounding factors such as medication and dropout rate.
- Plant parts used, extraction method and mode of administration.
- Blinding, whether the groups were randomised and whether the population had similar characteristics and were treated equally.
- Adverse effects.
- Consideration of the appropriateness of a narrative synthesis of the results if there is diversity of interventions.
- The necessity for further clinical research.
All included studies were considered as to their value with regard to methodology prior to drawing quantifiable and qualitative conclusions on the efficacy of the herbs evaluated. All studies had ethics approval.
4. Results: analysis and interpretation
In all, nine clinical studies were located, including four on M. officinalis, two on S. officinalis, and three on S. lavandulaefolia. The main characteristics of the studies are outlined in Table 2, page 19 (M. officinalis) and Table 3, page 20 (Salvia spp.). Studies are assigned numbers 1-9 for ease of identification.
4.1. Melissa officinalis
Study 1: Akhondzadeh et al. (2003a) assessed the efficacy of M. officinalis in patients with mild to moderate AD. Patients with other neurodegenerative disorders or psychiatric or organic diseases and those using anticholinergic or cholinomimetic drugs were excluded. Drugs for dementia and psychotropic drugs were discontinued. Patients were assessed before, during, and after the study by the Alzheimer’s Disease Assessment Scale (ADAS-cog) and the Clinical Dementia Rating Scoring Battery (CDR-SB). One patient in the Melissa group and six in the placebo group discontinued. After 16 weeks those in the Melissa group experienced significant improvement in cognition.
Study 2: Kennedy et al. (2003) assessed M. officinalis treatment for improvements in cognitive performance and mood enhancement in healthy young undergraduates. The Cognitive Drug Research (CDR) computerised cognitive assessment system was used for assessment of outcome at baseline, and 1 hour, 3 hours and 6 hours following administration of Melissa or placebo. Additionally, participants were assessed with a Rapid Visual Information Processing task (RVIP). Mood was assessed concurrently with a subjective mood measure. At the highest dose (1,600 mg) with peak at 6 hours, participants in the Melissa group reported a feeling of increased calmness and their memory improved but at the lower doses (Table 2) there was a decrement in memory.
Study 3: Kennedy et al. (2002) investigated cognitive performance and mood relative to dose and time course following single doses (Table 2) of M. officinalis in healthy, young undergraduates. The CDR test and serial subtraction tasks were used to assess cognitive performance and a subjective mood measure was employed concurrently. Testing was at baseline, 1, 2.5, 4 and 6 hours. The results did not support the role of M. officinalis as a memory-enhancing herb but subsequent in vitro testing of the extract found it had no cholinergic receptor binding properties.
Study 4: Modulation of mood and cognitive performance by M. officinalis at low doses (Table 2) during mild psychological stress was examined by Kennedy et al. (2004) in healthy young undergraduates. The Defined Intensity Stressor Stimulation (DISS) computerised battery test was used to assess mathematical, auditory, visual and memory processing. The results support the traditional use of M. officinalis as a cognition enhancer. Kennedy et al. (2004: 612) suggest it may be necessary to confirm the results in pathologically stressed patients.
The results of the studies on M. officinalis (Table 2) suggest 60 drops daily of fluid extract (FE) or a dose at or above 1,600 mg powdered leaf may be valuable in the prevention and treatment of dementia. Although impaired memory was noted at lower doses in two studies (Kennedy et al. 2002; 2003), these results conflict with another study (Kennedy et al. 2004) suggesting its efficacy as a cognition enhancer at 600 mg. Differences in source and preparation may have affected results. M. officinalis appears to be well tolerated and to have a calming effect. Kennedy et al. (2004: 612) propose that the sedating effect of M. officinalis may be via targeting of the GABA-ergic pathway.
4.2. Salvia officinalis
Study 5: Akhondzadeh et al. (2003b) assessed the efficacy and safety of S. officinalis in patients with mild to moderate AD. Exclusion criteria and patient assessment were as for Study 1 (Akhondzadeh et al. 2003a). Dropout rate was 4 for the Salvia group and 5 for placebo. Patients taking S. officinalis demonstrated significant improvement in cognition in comparison to those on placebo.
Study 6: Kennedy et al. (2006) assessed mood, anxiety and cognitive performance following two separate single doses (Table 3) of S. officinalis plus placebo in healthy young volunteers. Cognition was improved by 600 mg daily doses of dried herb.
Results of S. officinalis studies suggest its efficacy for cognition enhancement at 60 drops daily of 1: 1 FE or 600 mg daily of dried herb. The herb was well tolerated.
4.3. Salvia lavandulaefolia
Study 7: Perry et al. (2003) undertook a pilot tolerability and efficacy trial of S. lavandulaefolia EO at a range of doses (Table 3) in patients with mild to moderate AD. Patients with other known pathologies, with a history of alcohol or drug abuse or on medication for neuropathologies or psychiatric disorders were excluded. Patients were assessed with the CDR system, Neuropsychiatric Inventory (NPI) scores (Cummings et al. 1994) and MMSE at baseline and at 6 weeks. The EO was well tolerated except for a raise in blood pressure in two patients with a previous history of hypertension. As cognitive performance was measured only at baseline and after 6 weeks the study did not determine optimal dosage for cognitive enhancement.
Study 8: In two separate trials using different dose regimes (Table 3) Tildesley et al. (2003) assessed cognitive performance at baseline and 1, 2.5, 4, 5 and 6 hours with word recall exercises in healthy, young undergraduates. Cognitive performance was not significantly enhanced at the lowest or highest dose.
Study 9: Tildesley et al. (2005) investigated time and dose-dependent efficacy of S. lavandulaefolia EO on mood and cognitive performance in healthy, young undergraduates. Subjective mood ratings and CDR performance were assessed at baseline and 1, 2.5, 4, 5 and 6 hours. The results suggested S. lavandulaefolia EO enhanced cognitive performance and mood at both doses (Table 3) when compared to placebo.
The results of studies on S. lavandulaefolia suggest it has pharmacological efficacy for dementia at doses of 25 ml, 50 ml and 100 ml EO. It may not be advisable for those with hypertension to use Salvia spp.
Although the results of the clinical trials are promising none of the studies identified had sufficient methodological quality to provide conclusive scientific evidence to support traditional use of S. officinalis, S. lavandulaefolia or M. officinalis for cognitive enhancement. The tests for mood and anxiety are only subjective so there is also insufficient evidence for amelioration of agitation in dementia with these herbs.
Only one study (Kennedy et al. 2003) ensured the placebo and test substance were indistinct with regard to odour. Blinding poses difficulties in administration of aromatic herbs and insufficient blinding can affect results (Zick et al. 2005: 105). The aromas may have given clues to participants as to whether they were using placebo or treatment and could possibly be a confounding factor. The observational study on S. lavandulaefolia (Perry et al. 2003) was not blinded. According to a review of bias in trials of treatment efficacy non-blinded trials overestimate treatment effects by around 17% (Bandolier 2001: 2) due to observer bias.
Furthermore, none of the studies described whether randomisation was computerised to eliminate selection bias (Bandolier 2001: 1) and no reasons for dropouts, which may have caused the effects of the intervention to be over-estimated (Bandolier 3), were provided by Akhondzadeh et al. (2003a, b).
None of the studies was of sufficient duration or had enough participants to be conclusive. Small trials may overestimate treatment effects by 30% (Bandolier 2001: 2). There is insufficient evidence for long-term cognition enhancement with orthodox anti-cholinesterase drugs due to a lack of long-term studies (Loveman et al. 2006: 145), so longer studies with herbal therapeutics for cognition may also be needed.
Six of the studies used healthy, young volunteers with no cognitive impairment. The results may not be indicative of what would happen in the brains of elderly subjects with dementia if administered the same treatments.
The results for M. officinalis were conflicting but a fundamental problem with clinical trials of herbal medicines is standardisation. Within a given species comparability between different products or different types of extracts, for example essential oils, dried herbs and tinctures, and even different batches of similar extracts, is difficult as they lack equivalence (Linde et al. 2001). Chemical composition of an herbal preparation depends upon factors such as harvesting time, geographical source and the climate in which it was grown (dos Santos-Neto et al. 2006: 444).
The standardisation process may be based on irrelevant or insufficient ingredients (Andrade et al. 2000: 149). Whilst it may be of some use in providing scientific rationale for the bioactivity of a plant or plant part and to isolate and test various phytochemicals (Spinella 2002: 135), prescriptions in the herbal clinic are based on the premise that multiple phytochemicals contained in a plant are likely to act in synergy, not only with each other but with phytochemicals in other herbs dispensed concomitantly. This can be exemplified by the potential anti-inflammatory and antioxidant effects of rosmarinic acid (Iuvone et al. 2006: 1143), whereas EO was used in clinical trials of S. lavandulaefolia.
Clinical trials are mainly concentrated on herbs without thujone content due to its potential long-term toxicity (Tildesley et al. 2005: 700) yet it could be speculated that it may be a valuable component of S. officinalis and have a beneficial role to play in dementia. Evidence from human studies suggests that thujone is a GABAA receptor antagonist and may elevate mood by having an excitatory effect on the brain (Olsen 2000: 4418). GABA is an inhibitory neurotransmitter (Chebib et al. 2004: 14) and according to Birzniece et al. (2006: 219), loss of GABAA receptors in AD may contribute to severe depression and mood changes. However, there is evidence to suggest that GABAA antagonises human memory and learning (Chebib et al. 14) and clinical trials of GABA receptor antagonists for memory enhancement in AD are therefore underway (Association of the British Pharmaceutical Industry). Lending weight to this view is the promising evidence for the efficacy of Ginkgo biloba for cognitive enhancement (Birks and Grimley Evans 2002: 2) and the finding that bilobalide, a sesquiterpene in G. biloba is a GABAA receptor antagonist in vitro (Huang et al. 2003: 7). Hispidulin, a flavonoid in S. officinalis, is GABA-ergic and this action is potentially modulated by thujone (Johnson and Beart 2004: 809). It appears therefore that thujone may have an amphoteric effect on GABA, which further supports potential for plant chemicals acting in synergy for dementia. Additionally, thujone has shown significant antioxidant activity in vitro (Perry et al. 2001: 1352) and according to Chevalier (1996: 131) thujone imparts S. officinalis with oestrogenic properties.
More research is needed to determine the most valuable herbal approach to dementia. Most clinical studies of herbs for dementia have focused on their AChE inhibitory activity but it may transpire that the most effective therapies include multiple actions in addition to cholinesterase inhibition. More consideration needs to be applied to potential oestrogenic, antioxidant and anti-inflammatory actions of M. officinalis, S. officinalis and S. lavandulaefolia as supported by in vitro studies and for which there is clinical evidence for the value of these actions in dementia prevention. Furthermore, clinical trials to compare herbs with orthodox cognition enhancers would be interesting.
Other herbs with similar phytochemical constituents, and those for which evidence of efficacy from traditional use as memory-enhancers currently exists, could be investigated with a view to assessing whether they have similar benefits in relation to cognitive dysfunction. Many plants in the genus Salvia are currently under investigation for their nervous system effects (Imanshahidi and Hosseinzadeh 2006: 427) and an investigation of the diterpenes from the dried root of Salvia miltiorrhiza has demonstrated inhibition of AChE in vitro by tanshinones (Ren et al. 2004). Additionally, S. miltiorrhiza has been extensively studied in clinical trials for its cardiovascular protective benefits (Adams et al. 2006).
Assessment of the evidence from clinical trials of the efficacy of M. officinalis, S. officinalis or S. lavandulaefolia for prevention and treatment of Alzheimer’s disease or non-Alzheimer-type dementias is difficult due to conflicting results, inadequate experimental design and the difficulties inherent in clinical trials of herbal medicine. Despite these difficulties the results are promising and suggest M. officinalis, S. officinalis and S. lavandulaefolia improve cognitive function. As so, they have the potential to provide a non-toxic alternative to orthodox drugs for dementia.
In the short-term the results may provide an increased awareness of the potential for prevention, management and treatment with herbs of some of the devastating effects of dementia. In the long-term they may provide an impetus for more rigorous, long-term clinical studies with a greater number of participants.
The majority of clinical trials have been conducted on extracts standardised for AChE-inhibitory properties. It is hoped that others might endeavour to expand and progress this valuable work by using whole aerial part preparations to include phytochemicals that act in synergy to encompass all potential aetiologies for dementia. Additionally, there is a need to develop new ways of assessing optimum dosage, preparations, tolerability, efficacy and timescales in clinical trials. Only then can clinical practice be adequately informed.
The current limitations in knowledge regarding underlying mechanisms and risk factors in the pathogenesis of dementia are partly responsible for restricting the search for the most effective treatment modalities. Whilst cure of dementia continues to pose a challenge, those with known risks and younger patients with MCI could use potential preventative measures in the form of regular consumption of Melissa officinalis and Salvia spp concomitantly with other antioxidant, oestrogenic and anti-inflammatory herbs. A point to note is that Atropa belladonna, Datura stramomium or Hyoscymus niger contain the muscarinic receptor antagonist scopolamine (hyoscine), which may exacerbate memory loss (Perry et al. 1998: 532) and should not be prescribed to those at risk of dementia. In addition, advice on dietary and lifestyle changes to treat underlying risk factors such as vascular disease, hypertension and hyperglycaemia should be given. Neural plasticity may improve with exercise, learning activities and antioxidant nutrition (Jones et al. 2005: 7). Regular monitoring of progress with the MMSE may be useful in guiding the practitioner (Delagarza 2003: 1371) on alterations in prescription.
Adams DJ, Wang R, Yang J and Lien EJ (2006) Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chinese Medicine 2006, 1:3. Biomed Central. http://www.cmjournal.org/content/1/1/3 [accessed 30 April 2007].
Akhondzhadeh S, Norrozian M, Mohammadi M, Ohadinia S, Jamshidi AH & Khani M (2003a) Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery and Psychiatry 74, 863-866.
Akhondzhadeh S Norrozian M, Mohammadi M, Ohadinia S, Jamshidi AH & Khani M (2003b) Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double-blind, randomised and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics 28, 53-59.
Akhondzhadeh S & Abbasi SH (2006) Herbal medicine in the treatment of Alzheimer’s disease. American Journal of Alzheimer’s Disease and Other Dementias 21, 113-118.
Akomlafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA & Seshadri S (2006) Diabetes mellitus and risk of developing Alzheimer disease. Results from the Framlingham Study. Archives of Neurology 63, 1551-1555.
Alzheimer’s Society (2002) The Mini Mental State Examination (MMSE) – a guide for people with dementia and their carers. Alzheimer’s Society Quality Research in Dementia Information Sheet (June) 436.
Anekonda TS & Reddy PH (2005) Can herbs provide a new generation of drugs for treating Alzheimer’s disease? Brain Research Reviews 50, 361 – 376.
Andrade C, Sudha S & Venkataraman BV (2000) Herbal treatments for ECS-induced memory deficits: a review of research and a discussion of animal models. The Journal of ECT 16, 144-156.
The Association of the British Pharmaceutical Industry. Alzheimer’s and the pharmaceutical industry: Medicines for Alzheimer’s in the development pipeline. http://www.abpi.org.uk/publications/publication_details/targetAlzheimers/industry_c.asp [accessed 22 May 2007].
Bandolier (2001) Bandolier Bias Guide. Bandolier Extra (December), 1-5.
Barnes J, Anderson LA & Phillipson JD (2002) Herbal Medicines (2nd edn.) London: Pharmaceutical Press.
Beers MH, Porter RS, Jones TJ, Kaplan JL & Berkowits M (eds.) (2006) The Merck Manual of Diagnosis and Therapy (18th edn.). New Jersey: Merck Research Laboratories.
Bertelsen G, Christophersen C, Nielsen PH, Madsen HL & Stadel P (1995) Chromatographic isolation of antioxidants guided by a methyl linoleate assay. Journal of Agricultural and Food Chemistry 43, 1272-1275.
Bertram L, McQueen MB, Mullin K, Blacker D & Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Genetics 39, 17-23.
Biessels GJ (2004) Diabetes and dementia. European Endocrine Disease (December) 10-12.
Bird T D (2005) Genetic factors in Alzheimer’s disease. New England Journal of Medicine 352, 862-864.
Birks J & Grimley Evans J Ginkgo Biloba for cognitive impairment and dementia (Review) (2006) The Cochrane Collaboration. London: John Wiley & Sons, Ltd.
Birzniece V, Bäckströma T, Johanssona I, Lindblad C, Lundgrena P, Löfgren M, Olsson T, Ragagnina G, Taubea M, Turkmena S, Wahlströmc G, Wanga M, Wihlbäcka A & Zhua D (2006) Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Research Reviews 51, 212-239.
Breteler MMB, Claus JJ, van Dujin CM, Launer LJ & Hotman A (1992) Epidemiology of Alzheimer’s Disease. Epidemiologic Reviews 14, 59-82.
Chebib M, Hanrahan JR, Mewett KN, Duke RK & Johnston GAR (2004) Ionotropic GABA receptors as therapeutic targets for memory and sleep disorders. Annual Reports in Medicinal Chemistry 39, 13-23.
Chevallier A (2000) The Encyclopedia of Medicinal Plants (2nd edn.). London: Dorling Kindersley.
Collins RC (1997) Neurology. Philadelphia: WB Saunders Company.
Colucci M, Cammarata S, Assini A, Croce R, Clerici F, Novello C, Mazzella L, Dagnino N, Mariani C & Tanganelli P (2006) The number of pregnancies is a risk factor for Alzheimer’s disease. European Journal of neurology 13, 1374-1377.
Culpepper N (1826) Culpepper’s Complete Herbal and English Physician. (1981 reprint edition). Manchester: J. Gleave and Son.
Cummings JL, Mega MS, Gray K, Rosemberg-Thompson S, Gornbein T (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
Cuvelier M-E, Berset C & Richard H (1994) Antioxidant constituents in Sage (Salvia officinalis). Journal of Agricultural and Food Chemistry 42, 665-669.
Delagarza VW (2003) Pharmacologic treatment of Alzheimer’s disease: an update. American Family Physician 68, 1365-72.
De Leo V, Lanzetta D, Cazzavacca R & Morgante G (1998) Treatment of neurovegetative symptoms with a phytotherapeutic agent. Minerva Ginecologica 50, 207-211. [Abstract].
Dos Santos-Neto LL, de Vilhena Toledo MA, Medeiros-Souza PM & de Souza GA (2006) The use of herbal medicine in Alzheimer’s disease-a systematic review. Evidence-based Complementary and Alternative Medicine (eCAM) 3, 441-445.
Ernst E, Pittler MH (1999) Ginkgo biloba for dementia: a systematic review of double-blind, placebo-controlled trials. Clinical Drug Investigations 17, 301-308.
Ferreira A, Proenca C, Serralheiro MLM & Araujo MEM (2006) The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. Journal of Ethnopharmacology 108, 31-37.
Fleminger S, Oliver D L, Lovestone S, Rabe-Hesketh S & Giora A (2003) Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication. Journal of Neurology, Neurosurgery and Psychiatry 74, 857-862.
Forette F, Seux M, Staessen JA, Thijs L, Babarskine M, Babeanu S, Bassini A, Fagard R, Gill-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y & Birkenhager WH (2002) The prevention of dementia with antihypertensive treatment. Archives of Internal Medicine 162, 2046-2052.
Galvin JE, Powlishta KK, Wilkins K, Mckeel DW, Xiong C, Grant E, Storandt M & Morris JC (2005) Predictors of preclinical Alzheimer disease and dementia. Archives of Neurology 62, 758-765.
Grainger Bisset N & Wichtl M (Eds.) (2001) Herbal Drugs and Phytopharmaceuticals (2nd edn.). Stuttgart, Germany: GmbH Scientific Publishers (1994).
Grieve M (1931) A Modern Herbal. Botanical.com. http://www.botanical.com/botanical/mgmh/b/balm–02.html [accessed 20 April 2007]
Grossman H, Bergmann C & Parker S (2006) Dementia: a brief review. The Mount Sinai Journal of Medicine 73, 985-992.
Heinrich M, Barnes J, Gibbons S & Williamson E (2004) Fundamentals of Pharmacognosy and Phytotherapy. London: Churchill Livingstone.
Hoskin EK, Tang MX, Manly JJ & Moyeux R (2004) Elevated sex hormone binding globulin in elderly women with Alzheimer’s disease. Neurology of Aging 25, 141-147.
Houghton PJ & Howes MJ (2005) Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease. Neurosignals 14, 6-22.
Howes M R, Perry NSL & Houghton P (2003) Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and other cognitive disorders. Phytotherapy Research 17, 1-18.
Huang SH, Duke RK, Chebib M, Keiko Sasaki K, Wada K, Graham KW, Johnston AR (2003) Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant a1b2g2L GABAA receptors. European Journal of Pharmacology 464, 1- 8.
Imanshahidi M and Hosseinzadeh H (2006) The pharmacological effects of Salvia species on the central nervous system. Phytotherapy Research 20, 427-437.
Iuvone T, De Filippis D, Esposito G, D’Amico A, A. Izzo A (2006) The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-ß peptide-induced neurotoxicity. Journal of Pharmacology and Experimental Therapeutics 317, 1143-1149.
Ivanova D, Gerova D, Chervenkov T & Yankova T (2005) Polyphenols and antioxidant capacity of Bulgarian medicinal plants. Journal of Ethnopharmacology 96, 145-150.
Johnston GAR & Beart PM (2004) Flavonoids: some of the wisdom of sage? British Journal of Pharmacology 142, 809-810.
Jones R, Morris K & Nutt D (2005) Cognition Enhancers. Foresight Brain Science, Addiction and Drugs Project, 1-44.
Kavvadias D, Monschein V, Sand P, Riedere P & Schreier P (2003) Constituents of Sage (Salvia officinalis) with in vitro Affinity to human brain benzodiazepine receptor. Planta Medica 69,113-117
Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK & Wesnes KA (2002) Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology, Biochemistry and Behavior 72, 953-964.
Kennedy DO, Wake G, Tildesley NTJ, Perry EK, Wesnes KA & Scholey AB (2003) Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology 28, 1871-1881.
Kennedy DO, Little W & Scholey AB (2004) Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosomatic Medicine 66, 607-633.
Kennedy DO & Scholey AB (2006) The psychopharmacology of European herbs with cognition-enhancing properties. Current Pharmaceutical Design 12, 4613-4623.
Kennedy DO, Pace S, Haskell C, Okello EJ, Milne A & Scholey AB (2006) Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery. Neuropsychopharmacology 31, 845-852.
Kidd PM (1999) A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Alternative Medicine Review 4, 144-161.
Knapp M, Prince M, Albanese E, Banerjee S, Dhanasiri S, Fernandez J, Ferri C, McCrone P, Snell T & Stewart R (2007) Dementia UK. London: Alzheimer’s Society.
Kimura Y, Okuda H, Okuda T, Hatano T & Arichi S (1987) Studies on the activities of tannins and related compounds, X. Effects of caffeetannins and related compounds on arachidonate metabolism in human polymorphonuclear leukocytes. Journal of Natural Products 50, 392-399.
Levy A, Lah J, Goldstein F, Steenland K & Bliwise D (2006) Mild cognitive impairment: An opportunity to identify patients at high risk for progression to Alzheimer’s disease. Clinical Therapeutics 26, 991-1802.
Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC & Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. American Journal of Epidemiology 145, 301-308.
Lima CF, Valentao PCR, Andrade PB, Seabra RM, Fernandes-Ferreira M & Pereira-Wilson C (2007) Water and methanolic extracts of Salvia officinalis protect HepG2 cells from t-BHP induced oxidative damage. Chemico-Biological Interactions 167, 107-115.
Linde K, Riet G, Hondras M, Vickers A, Saller R & Melchart D (2001) Systematic reviews of complementary therapies – an annotated bibliography. Part 2: Herbal medicine. BMC Complementary and Alternative Medicine (2001) 1:5. http://www.biomedcentral.com/1472-6882/1/5. pdf [accessed 13 April 2007].
Lipp FJ (1996) Herbalism. London: Macmillan.
Looi JCL & Sachdev PS (1999) Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 53, 670-678.
Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E & Clegg A (2006) The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technology Assessment 10, 1-160.
Maggini M, Vanacore N & Raschetti R (2006) Cholinesterase inhibitors: Drugs looking for a disease? Public Library of Science Medicine 3, 456-460.
Mantle D, Pickering AT & Perry EK (2000) Medicinal extracts for the treatment of dementia. A review of their pharmacology, efficacy and tolerability. CNS Drugs 13, 201-213.
Marongiu B, Pocedda S, Piras A, Rosa A, Delana M & Assunta Dessi M (2004) Antioxidant activity of supercritical extract of Melissa officinalis Subsp. officinalis and Melissa officinalis Subsp. inodora. Phytotherapy Research 18, 789-792.
Maurer MH & Kuschinsky W (2006) Screening the Brain: Molecular Fingerprints of Neural Stem Cells. Current Stem Cell Research & Therapy 65-77.
Micieli G (2006) Vascular dementia. Neurological Sciences 27, S37-S39.
Miura K, Kikuzaki H & Nakatani N (2002) Antioxidant activity of chemical components from sage (Salvia officinalis L.) and thyme (Thymus vulgaris L.) measured by the oil stability index method. Journal of Agricultural and Food Chemistry 50, 1845-1851.
Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM & Resnick SM (2004)Free testosterone and risk for Alzheimer disease in older men. Neurology 62, 188-193.
Mortimer JA, Van Duijn CM, Chandra V, L Fratiglioni, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K & Rocca WA (1991) Head trauma as a risk factor for Alzheimer’s disease: a collaborative re-analysis of case-control studies. International Journal of Epidemiology 20, S28-35. Abstract.
Oken BS, Storzbach DM, Kaye JA (1998) The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Archives of Neurology 55, 1409-1415.
Olsen RW (2000) Absinthe and g-aminobutyric acid receptors. Proceedings of the national Academy of Sciences 97, 4417-4418.
Page R (1978) Cures and Remedies the Country Way. London: Davis-Poynter.
Perry N, Court G, Bidet N, Court J & Perry E (1996) European herbs with cholinergic activities: potential in dementia therapy. International Journal of Geriatric Psychiatry 11, 1063-1069.
Perry EK, Pickering AT, Wang WW, Houghton P & Perry NSL (1998) Medicinal plants and Alzheimer’s disease: integrating ethnobotanical and contemporary scientific evidence. The Journal of Alternative and Complementary Medicine 4, 419-428.
Perry EK, Pickering AT, Wang WW, Houghton PJ & Perry NS (1999) Medicinal plants and Alzheimer’s disease: from ethnobotany to phytotherapy. Journal of Pharmacy and Pharmacology 51, 527-534.
Perry NSL, Houghton PJ, Theobald A, Jenner P & Perry EK (2000) In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. Journal of Pharmacy and Pharmacology 52, 895-902.
Perry NSL, Houghton PJ, Sampson J, Theobald AE, Hart S, Lis-balchin M, Hoult JRS, Evans P, Jenner P, Milligan S & Perry EK (2001) In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer’s disease. Journal of Pharmacy and Pharmacology 53, 1347-1356.
Perry NSL, Bollenb C, Perry EK & Ballard C (2003) Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacology, Biochemistry and Behavior 75 (2003) 651-659.
Pizzale L, Bortolomeazzi R, Vichi S, Überegger E & Conte LS (2002) Antioxidant activity of sage (Salvia officinalis and S fruticosa) and oregano (Origanum onites and O. indercedens) extracts related to their phenolic compound content. Journal of the Science of Food and Agriculture 82, 1645-1651.
Reddy PH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer’s disease. Jour